Sysmex (TSE:6869) Second Quarter 2025 Results
Key Financial Results
- Revenue: JP¥130.5b (up 11% from 2Q 2024).
- Net income: JP¥15.0b (up 10% from 2Q 2024).
- Profit margin: 12% (in line with 2Q 2024).
- EPS: JP¥24.01 (up from JP¥21.60 in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sysmex EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%.
Looking ahead, revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Japan.
Performance of the Japanese Medical Equipment industry.
The company's shares are up 13% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Sysmex's balance sheet health.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:6869
Sysmex
Engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan.
Solid track record with excellent balance sheet.